Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
ACADIA Pharmaceuticals Inc. Stock Price (Quote) NASDAQ:ACAD
$23.05 ( 4.11% ) Friday, 14th Jan 2022
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $20.84 | $27.19 | Friday, 14th Jan 2022 ACAD stock ended at $23.05. This is 4.11% more than the trading day before Thursday, 13th Jan 2022. During the day the stock fluctuated 6.51% from a day low at $21.66 to a day high of $23.07. |
| 90 days | $16.87 | $27.19 | |
| 52 weeks | $15.68 | $54.73 |
Historical ACADIA Pharmaceuticals Inc. prices
| Date | Open | High | Low | Close | Volume |
| 2022-01-14 | $21.86 | $23.07 | $21.66 | $23.05 | 1 342 008 |
| 2022-01-13 | $22.20 | $22.77 | $21.63 | $22.14 | 1 476 345 |
| 2022-01-12 | $22.68 | $22.80 | $21.85 | $22.14 | 1 759 323 |
| 2022-01-11 | $22.65 | $23.30 | $22.32 | $22.75 | 600 368 |
| 2022-01-10 | $22.63 | $22.78 | $21.67 | $22.71 | 1 493 076 |
| 2022-01-07 | $23.05 | $23.64 | $22.54 | $22.59 | 1 316 177 |
| 2022-01-06 | $23.38 | $24.08 | $22.64 | $23.39 | 1 007 700 |
| 2022-01-05 | $24.36 | $24.99 | $23.10 | $23.11 | 1 652 125 |
| 2022-01-04 | $24.39 | $24.59 | $23.38 | $23.62 | 984 421 |
| 2022-01-03 | $23.33 | $24.55 | $23.12 | $24.39 | 915 186 |
| 2021-12-31 | $23.66 | $23.73 | $22.94 | $23.34 | 825 359 |
| 2021-12-30 | $23.92 | $24.20 | $23.51 | $23.54 | 813 759 |
| 2021-12-29 | $24.60 | $24.74 | $23.87 | $23.96 | 723 899 |
| 2021-12-28 | $24.34 | $25.09 | $24.29 | $24.67 | 1 064 027 |
| 2021-12-27 | $24.17 | $24.74 | $23.90 | $24.32 | 1 032 148 |
| 2021-12-23 | $23.85 | $24.58 | $23.37 | $24.30 | 2 036 266 |
| 2021-12-22 | $21.51 | $24.01 | $21.21 | $23.92 | 3 880 228 |
| 2021-12-21 | $25.16 | $25.29 | $20.84 | $21.45 | 8 060 117 |
| 2021-12-20 | $25.50 | $27.19 | $24.94 | $27.09 | 3 957 350 |
| 2021-12-17 | $24.73 | $26.33 | $24.36 | $25.76 | 5 813 277 |
| 2021-12-16 | $24.17 | $24.85 | $23.91 | $24.79 | 1 913 398 |
| 2021-12-15 | $23.13 | $24.42 | $22.19 | $24.38 | 1 848 975 |
| 2021-12-14 | $22.55 | $23.47 | $22.42 | $23.00 | 1 302 518 |
| 2021-12-13 | $22.30 | $23.25 | $22.21 | $22.90 | 1 508 916 |
| 2021-12-10 | $22.61 | $23.15 | $22.13 | $22.26 | 1 294 804 |
| 2021-12-09 | $21.74 | $23.35 | $21.57 | $22.62 | 1 988 885 |
| 2021-12-08 | $21.59 | $21.96 | $21.12 | $21.78 | 1 597 675 |
| 2021-12-07 | $21.80 | $21.86 | $19.81 | $21.32 | 5 757 934 |
| 2021-12-06 | $18.82 | $19.49 | $18.50 | $19.40 | 2 514 559 |
| 2021-12-03 | $20.00 | $20.00 | $18.50 | $18.79 | 1 155 303 |
| 2021-12-02 | $18.90 | $19.99 | $18.75 | $19.94 | 1 078 703 |
| 2021-12-01 | $19.01 | $19.98 | $18.87 | $18.90 | 1 022 025 |
| 2021-11-30 | $18.65 | $19.24 | $18.57 | $19.20 | 1 135 812 |
| 2021-11-29 | $19.07 | $19.49 | $18.82 | $18.84 | 1 092 385 |
| 2021-11-26 | $19.45 | $19.90 | $18.58 | $18.79 | 890 361 |
| 2021-11-24 | $19.32 | $19.97 | $19.04 | $19.78 | 676 953 |
| 2021-11-23 | $19.21 | $19.55 | $18.79 | $19.49 | 950 795 |
| 2021-11-22 | $19.01 | $19.63 | $18.96 | $19.29 | 885 546 |
| 2021-11-19 | $18.93 | $19.53 | $18.85 | $19.15 | 730 630 |
| 2021-11-18 | $19.59 | $19.67 | $18.82 | $18.95 | 1 515 527 |
| 2021-11-17 | $20.27 | $20.75 | $19.39 | $19.48 | 1 258 040 |
| 2021-11-16 | $19.83 | $20.48 | $19.43 | $20.46 | 2 377 695 |
| 2021-11-15 | $20.91 | $20.93 | $19.75 | $19.77 | 1 278 804 |
| 2021-11-12 | $20.73 | $20.85 | $20.42 | $20.65 | 1 044 274 |
| 2021-11-11 | $20.31 | $21.20 | $20.31 | $20.68 | 761 472 |
| 2021-11-10 | $21.56 | $21.66 | $20.28 | $20.34 | 1 476 938 |
| 2021-11-09 | $20.84 | $21.88 | $20.69 | $21.57 | 1 739 258 |
| 2021-11-08 | $20.18 | $20.60 | $19.36 | $19.57 | 1 765 768 |
| 2021-11-05 | $20.00 | $20.11 | $19.53 | $20.02 | 1 005 151 |
| 2021-11-04 | $20.24 | $20.57 | $19.91 | $20.02 | 951 215 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzh... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 100 000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
